198 related articles for article (PubMed ID: 19549672)
1. Anti-acanthamoeba efficacy and toxicity of miltefosine in an organotypic skin equivalent.
Walochnik J; Obwaller A; Gruber F; Mildner M; Tschachler E; Suchomel M; Duchêne M; Auer H
J Antimicrob Chemother; 2009 Sep; 64(3):539-45. PubMed ID: 19549672
[TBL] [Abstract][Full Text] [Related]
2. Weak cytotoxic activity of miltefosine against clinical isolates of Acanthamoeba spp.
Mrva M; Garajová M; Lukáč M; Ondriska F
J Parasitol; 2011 Jun; 97(3):538-40. PubMed ID: 21506779
[TBL] [Abstract][Full Text] [Related]
3. In-vitro activity of miltefosine and voriconazole on clinical isolates of free-living amebas: Balamuthia mandrillaris, Acanthamoeba spp., and Naegleria fowleri.
Schuster FL; Guglielmo BJ; Visvesvara GS
J Eukaryot Microbiol; 2006; 53(2):121-6. PubMed ID: 16579814
[TBL] [Abstract][Full Text] [Related]
4. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis.
Dorlo TP; Balasegaram M; Beijnen JH; de Vries PJ
J Antimicrob Chemother; 2012 Nov; 67(11):2576-97. PubMed ID: 22833634
[TBL] [Abstract][Full Text] [Related]
5. Miltefosine: oral treatment of leishmaniasis.
Soto J; Soto P
Expert Rev Anti Infect Ther; 2006 Apr; 4(2):177-85. PubMed ID: 16597200
[TBL] [Abstract][Full Text] [Related]
6. [Miltefosine: a new remedy for leishmaniasis].
Dorlo TP; Eggelte TA; Beijnen JH; de Vries PJ
Ned Tijdschr Geneeskd; 2006 Dec; 150(49):2697-701. PubMed ID: 17194005
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs.
Seifert K; Croft SL
Antimicrob Agents Chemother; 2006 Jan; 50(1):73-9. PubMed ID: 16377670
[TBL] [Abstract][Full Text] [Related]
8. Miltefosine--discovery of the antileishmanial activity of phospholipid derivatives.
Croft SL; Engel J
Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S4-8. PubMed ID: 16904717
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic activities of alkylphosphocholines against clinical isolates of Acanthamoeba spp.
Walochnik J; Duchêne M; Seifert K; Obwaller A; Hottkowitz T; Wiedermann G; Eibl H; Aspöck H
Antimicrob Agents Chemother; 2002 Mar; 46(3):695-701. PubMed ID: 11850250
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological activity of dialkylphosphocholines.
Lukác M; Mrva M; Fischer-Fodor E; Lacko I; Bukovský M; Miklásová N; Ondriska F; Devínsky F
Bioorg Med Chem Lett; 2009 Nov; 19(22):6346-9. PubMed ID: 19818608
[TBL] [Abstract][Full Text] [Related]
11. Treatment of leishmaniasis with miltefosine: 2008 status.
Berman JJ
Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1209-16. PubMed ID: 18721114
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Bolivian mucosal leishmaniasis with miltefosine.
Soto J; Toledo J; Valda L; Balderrama M; Rea I; Parra R; Ardiles J; Soto P; Gomez A; Molleda F; Fuentelsaz C; Anders G; Sindermann H; Engel J; Berman J
Clin Infect Dis; 2007 Feb; 44(3):350-6. PubMed ID: 17205440
[TBL] [Abstract][Full Text] [Related]
13. Miltefosine and polyhexamethylene biguanide: a new drug combination for the treatment of Acanthamoeba keratitis.
Polat ZA; Walochnik J; Obwaller A; Vural A; Dursun A; Arici MK
Clin Exp Ophthalmol; 2014 Mar; 42(2):151-8. PubMed ID: 23601234
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo.
Seifert K; Pérez-Victoria FJ; Stettler M; Sánchez-Cañete MP; Castanys S; Gamarro F; Croft SL
Int J Antimicrob Agents; 2007 Sep; 30(3):229-35. PubMed ID: 17628445
[TBL] [Abstract][Full Text] [Related]
15. Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine.
Dorlo TP; Balasegaram M; Lima MA; de Vries PJ; Beijnen JH; Huitema AD
J Antimicrob Chemother; 2012 Aug; 67(8):1996-2004. PubMed ID: 22577099
[TBL] [Abstract][Full Text] [Related]
16. Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses.
Zerpa O; Ulrich M; Blanco B; Polegre M; Avila A; Matos N; Mendoza I; Pratlong F; Ravel C; Convit J
Br J Dermatol; 2007 Jun; 156(6):1328-35. PubMed ID: 17441955
[TBL] [Abstract][Full Text] [Related]
17. Oral miltefosine for the treatment of Indian visceral leishmaniasis.
Sundar S; Jha TK; Thakur CP; Bhattacharya SK; Rai M
Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S26-33. PubMed ID: 16730038
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of miltefosine for topical treatment of Acanthamoeba keratitis in Syrian hamsters.
Polat ZA; Obwaller A; Vural A; Walochnik J
Parasitol Res; 2012 Feb; 110(2):515-20. PubMed ID: 21748351
[TBL] [Abstract][Full Text] [Related]
19. Opportunistic amoebae: challenges in prophylaxis and treatment.
Schuster FL; Visvesvara GS
Drug Resist Updat; 2004 Feb; 7(1):41-51. PubMed ID: 15072770
[TBL] [Abstract][Full Text] [Related]
20. Miltefosine promotes IFN-gamma-dominated anti-leishmanial immune response.
Wadhone P; Maiti M; Agarwal R; Kamat V; Martin S; Saha B
J Immunol; 2009 Jun; 182(11):7146-54. PubMed ID: 19454711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
